Search results
Results From The WOW.Com Content Network
This is a list of investigational hallucinogens and entactogens, or hallucinogens and entactogens that are currently under formal development for clinical use but are not yet approved. [ 1 ] Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.
A large epidemiological study in the U.S. found that other than personality disorders and other substance use disorders, lifetime hallucinogen use was not associated with other mental disorders, and that risk of developing a hallucinogen use disorder was very low. [67]
The toxic berry of Atropa belladonna which contains the tropane deliriants scopolamine, atropine, and hyoscyamine.. Deliriants are a subclass of hallucinogen.The term was coined in the early 1980s to distinguish these drugs from psychedelics such as LSD and dissociatives such as ketamine, due to their primary effect of causing delirium, as opposed to the more lucid (i.e. rational thought is ...
The Maya, Olmecs, and Aztecs have well-documented entheogenic complexes. [3] North American cultures also have a tradition of entheogens. In South America, especially in Peru, the archaeological study of cultures like Chavin, Cupisnique, Nazca [4] and Moche, [5] have demonstrated the use of entheogens through archaeobotanical, iconographic and paraphernalia.
Dental anesthesia (or dental anaesthesia) is the application of anesthesia to dentistry. It includes local anesthetics , sedation , and general anesthesia. Local anesthetic agents in dentistry
Mescaline, also known as mescalin or mezcalin, [8] and in chemical terms 3,4,5-trimethoxyphenethylamine, is a naturally occurring psychedelic protoalkaloid of the substituted phenethylamine class, known for its hallucinogenic effects comparable to those of LSD and psilocybin.
Dental patients with generalized anxiety, belonephobia (fear of needles and sharp instruments), prior dental trauma, or generalized fear of the dentist can take oral medication in order to reduce their anxieties. [3] A variety of single and incremental dose protocols are used to medicate the patient as early as the day before treatment. [4]
In 1943, Albert Hofmann discovered the hallucinogenic effects of LSD that led to an altered state of consciousness. [5] [6]In 1947, Gion Condrau and Arthur Stoll [5] [7] [8] [9] [6] observed that people diagnosed as "psychotics" had a stronger tolerance for LSD and that the effects of the drug were similar to the symptoms expressed by psychotics themselves.